Market NewsPeptron surges more than 16% on news of domestic production plans for obesity drug ‘Mounjaro’

Peptron(087010) rallied sharply on the morning of November 28 after reports that Eli Lilly, the world’s largest pharmaceutical company by market capitalization, is preparing to establish a production base in Korea for its obesity treatment “Mounjaro.”

As of 9:57 a.m., Peptron was trading at 359,000 won on the KOSDAQ, up 51,000 won (16.56%) from the previous session.

Eli Lilly is reportedly pursuing a plan to build an integrated production system for Mounjaro in the North Chungcheong region, and Peptron is being mentioned as a potential partner for finished-product manufacturing. Peptron holds proprietary technology for long-acting peptide injectable formulations used in obesity treatments.

Eli Lilly has also been conducting joint research with Peptron since October last year to evaluate Peptron’s long-acting drug-delivery platform “SmartDepot.”